Take Homes in Multiple Myeloma

Take Homes in Multiple Myeloma

Source:

Usmani SZ, et al. Abstract 8005. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
June 24, 2021
1 min watch
Save

VIDEO: Ciltacabtagene autoleucel yields “phenomenal” response in multiple myeloma

Source:

Usmani SZ, et al. Abstract 8005. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The last few years have yielded “incredible numbers of new drugs approved and under development” in multiple myeloma, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.

This includes the FDA approval of idecabtagene vicleucel (Abecma; Bristol Myers Squibb, bluebird bio), the first CAR T-cell therapy for multiple myeloma, based on findings from the KarMMa trial. At the virtual ASCO Annual Meeting, updated data on another CAR T-cell therapy, ciltacabtagene autoleucel (Janssen, Legend Biotech) was presented from the ongoing CARTITUDE-1 trial.

“We were very impressed by the overall responses observed in some of the studies, including very deep responses ... but the durability was not like we expected,” Gasparetto said. “But Dr. Usmani at ASCO presented the updated CARTITUDE 1 ... and I was pleasantly surprised to see not only the phenomenal overall response – above 90% and lots of people achieving MRD – and the durability, the progression-free survival with a longer follow-up of 21 months. We are definitely seeing better results.”